Bernard G Jaar

Dr. Bernard G Jaar

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2004 in JAMA
Verified
Journal Article
Open access
PDF file
YLYongmei Liu
Yongmei Liu
JCJosef Coresh
Josef Coresh
JEJoseph A. Eustace
Joseph A. Eustace
JLJ. Craig Longenecker
J. Craig Longenecker
BJBernard G Jaar
Bernard G Jaar
MKMichael J. Klag
Michael J. Klag
Research from JAMA — Association Between Cholesterol Level and Mortality in Dialysis Patients — Role of Inflammation and Malnutrition — ContextTotal cholesterol level is inversely associated with mortality in dialysis patients, a group at high risk of cardiovascular disease (CVD). This paradox may be explained by systemic inflammation and/or malnutrition, which are associated with lower cholesterol levels and higher mortality.ObjectiveTo determine the relationship between cholesterol level and outcome in patients undergoing dialysis, accounting for inflammation and malnutrition.Design, Setting, and ParticipantsProspective study of 823 patients enrolled from October 1995 to June 1998 who recently initiated dialysis, from 79 clinics, classified by absence or presence of inflammation and/or malnutrition (defined as serum albumin levels <3.6 mg/dL, C-reactive protein ≥10 mg/L, or interleukin 6 ≥3.09 pg/mL).Main Outcome MeasuresAll-cause and cardiovascular disease mortality.ResultsDuring a median follow-up of 2.4 years, 324 deaths (159 CVD deaths), 153 renal transplantations, and 10 losses to follow-up occurred. Average serum cholesterol level was lower in the presence of inflammation/malnutrition than in its absence. In a Cox model adjusted for age, race, and sex, a 40-mg/dL (1.0-mmol/L) increment in baseline total serum cholesterol level was associated with a decreased risk of all-cause mortality overall (relative hazard [RH], 0.92; 95% confidence interval [CI], 0.87-0.98) and in the presence of inflammation/malnutrition (RH, 0.89; CI, 0.84-0.95). In contrast, serum cholesterol level was associated with an increased risk in the absence of inflammation/malnutrition (RH, 1.32; 95% CI, 1.07-1.63). For CVD mortality, an inverse trend was not statistically significant in the presence of inflammation/malnutrition, and a positive association was evident in the absence of inflammation/malnutrition (RH, 1.41; 95% CI, 1.04-1.89). Further adjustment for traditional CVD risk factors, dialysis modality, comorbidity, and inflammatory markers attenuated the inverse association but strengthened the positive association.ConclusionsThe inverse association of total cholesterol level with mortality in dialysis patients is likely due to the cholesterol-lowering effect of systemic inflammation and malnutrition, not to a protective effect of high cholesterol concentrations. These findings support treatment of hypercholesterolemia in this population.

1 November 2003 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
MHMelanie K. Haroun
Melanie K. Haroun
BJBernard G Jaar
Bernard G Jaar
SHSandra C. Hoffman
Sandra C. Hoffman
GCGeorge W. Comstock
George W. Comstock
MKMichael J. Klag
Michael J. Klag
JCJosef Coresh
Josef Coresh
: Chronic kidney disease (CKD) is an increasing cause of morbidity and mortality in the United States. Prospective data on risk factors for CKD are limited to men, and few studies examine the importance of smoking. The authors performed a community-based, prospective observational study of 20-yr duration to examine the association between hypertension and smoking on the future risk of CKD in 23,534 men and women in Washington County, Maryland. CKD was identified as end-stage renal disease in the Health Care Financing Administration database or kidney disease listed on the death certificate. All cases were confirmed as CKD by medical chart review. Adjusted relative hazards of CKD were modeled using Cox proportional hazards regression including age as the time variable and baseline BP, cigarette smoking, gender, and diabetes status as risk factors. The adjusted hazard ratio (95% confidence interval) of developing CKD among women was 2.5 (0.05 to 12.0) for normal BP, 3.0 (0.6 to 14.4) for high-normal BP, 3.8 (0.8 to 17.2) for stage 1 hypertension, 6.3 (1.3 to 29.0) for stage 2 hypertension, and 8.8 (1.8 to 43.0) for stages 3 or 4 hypertension compared with individuals with optimal BP. In men, the relationship was similar but somewhat weaker than in women, with corresponding hazard ratios of 1.4 (0.2 to 12.1), 3.3 (0.4 to 25.6), 3.0 (0.4 to 22.2), 5.7 (0.8 to 43.0), and 9.7 (1.2 to 75.6), respectively. Current cigarette smoking was also significantly associated with risk of CKD in both men and women (hazard ratio in women 2.9 [1.7 to 5.0] and in men 2.4 [1.5 to 4.0]). A large proportion of the attributable risk of CKD in this population was associated with stage 1 hypertension (23%) and cigarette smoking (31%). In conclusion, CKD risk shows strong graded relationships to the sixth report of the Joint National Committee (JNC-VI) on Prevention, Detection Evaluation and Treatment of High BP criteria for BP, to diabetes, and to current cigarette smoking that are at least as strong in women as in men. E-mail: coresh@jhu.edu

27 May 2013 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
MMMara A. McAdams‐DeMarco
Mara A. McAdams‐DeMarco
ALAndrew Law
Andrew Law
MSMegan L. Salter
Megan L. Salter
BBBrian Boyarsky Ba
Brian Boyarsky Ba
LGLuis Gimenez
Luis Gimenez
DSDorry Segev
Dorry Segev

1 March 1999 in Kidney International
Verified
Journal Article
Open access
NPNeil R. Powe
Neil R. Powe
BJBernard G Jaar
Bernard G Jaar
SFSusan L. Furth
Susan L. Furth
JHJudith Hermann
Judith Hermann
WBWilliam Briggs
William Briggs
Infection is second to cardiovascular disease as a cause of death in patients with end-stage renal disease (ESRD), and septicemia causes a majority of these infectious deaths. To identify patients at high risk and to characterize modifiable risk factors for septicemia, we examined the incidence, risk factors, and prognosis for septicemia in a large, representative group of U.S. dialysis patients. We conducted a longitudinal cohort study of incident ESRD patients in the case-mix study of the U.S. Renal Data System with seven years of follow-up from hospitalization and death records. Poisson regression was used to examine independent risk factors for hospital-managed septicemia. Cox proportional hazards analysis was used to assess the independent effect of septicemia on all-cause mortality and on death from septicemia. Separate analyses were performed for patients on peritoneal dialysis (PD) and hemodialysis (HD). Over seven years of follow-up, 11.7% of 4005 HD patients and 9.4% of 913 PD patients had at least one episode of septicemia. Older age and diabetes were independent risk factors for septicemia in all patients. Among HD patients, low serum albumin, temporary vascular access, and dialyzer reuse were also associated with increased risk. Among PD patients, white race and having no health insurance at dialysis initiation were also risk factors. Patients with septicemia had twice the risk of death from any cause and a fivefold to ninefold increased risk of death from septicemia. Septicemia, which carries a marked increased risk of death, occurs frequently in patients on PD as well as HD. Early referral to a nephrologist, improving nutrition, and avoiding temporary vascular access may decrease the incidence of septicemia. Further study of how race, insurance status, and dialyzer reuse can contribute to the risk of septicemia among ESRD patients is indicated.

21 August 2009 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
ANAna Navas-Acien
Ana Navas-Acien
MTMaria Tellez-Plaza
Maria Tellez-Plaza
EGEliseo Guallar
Eliseo Guallar
PMPaul Muntner
Paul Muntner
ESEllen Silbergeld
Ellen Silbergeld
VWVirginia Weaver
Virginia Weaver
Environmental cadmium and lead exposures are widespread, and both metals are nephrotoxic at high exposure levels. Few studies have evaluated the associations between low-level cadmium and clinical renal outcomes, particularly with respect to joint cadmium and lead exposure. The geometric mean levels of blood cadmium and lead were 0.41 μg/L (3.65 nmol/L) and 1.58 μg/dL (0.076 μmol/L), respectively, in 14,778 adults aged ≥20 years who participated in the National Health and Nutrition Examination Survey (1999–2006). After adjustment for survey year, sociodemographic factors, chronic kidney disease risk factors, and blood lead, the odds ratios for albuminuria (≥30 mg/g creatinine), reduced estimated glomerular filtration rate (eGFR) (<60 mL/minute/1.73 m2), and both albuminuria and reduced eGFR were 1.92 (95% confidence interval (CI): 1.53, 2.43), 1.32 (95% CI: 1.04, 1.68), and 2.91 (95% CI: 1.76, 4.81), respectively, comparing the highest with the lowest blood cadmium quartiles. The odds ratios comparing participants in the highest with the lowest quartiles of both cadmium and lead were 2.34 (95% CI: 1.72, 3.18) for albuminuria, 1.98 (95% CI: 1.27, 3.10) for reduced eGFR, and 4.10 (95% CI: 1.58, 10.65) for both outcomes. These findings support consideration of cadmium and lead as chronic kidney disease risk factors in the general population and provide novel evidence of risk with environmental exposure to both metals.

17 December 2003 in JAMA
Verified
Journal Article
Open access
PDF file
LBL. Ebony Boulware
L. Ebony Boulware
BJBernard G Jaar
Bernard G Jaar
MTMichelle E. Tarver-Carr
Michelle E. Tarver-Carr
FBFrederick L. Brancati
Frederick L. Brancati
NPNeil R. Powe
Neil R. Powe
Chronic kidney disease is a growing public health problem. More than 10 million US adults have some kidney damage (serum creatinine levels ≥1.5 mg/dL [132.6 µmol/L]), and the number of persons with end-stage renal disease (ESRD) exceeds 300 000. Persons with ESRD, who have a poor quality of life and accrue high health care costs, are projected to exceed 600 000 in 2010.1-4 Early identification and treatment of patients who are more likely to progress to ESRD to decrease mortality, morbidity, and costs associated with chronic kidney disease has been debated. Controversy exists because many patients do not progress to ESRD, however, the majority of those who do progress go undetected until it is too late to intervene.5